Edesa Biotech (STU:RBTQ) Change In Receivables : €-0.99 Mil (TTM As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Edesa Biotech Change In Receivables?

Edesa Biotech's change in receivables for the quarter that ended in Mar. 2024 was €-0.35 Mil. It means Edesa Biotech's Accounts Receivable increased by €0.35 Mil from Dec. 2023 to Mar. 2024 .

Edesa Biotech's change in receivables for the fiscal year that ended in Sep. 2023 was €0.53 Mil. It means Edesa Biotech's Accounts Receivable declined by €0.53 Mil from Sep. 2022 to Sep. 2023 .

Edesa Biotech's Accounts Receivable for the quarter that ended in Mar. 2024 was €1.02 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Edesa Biotech's liquidation value for the three months ended in Mar. 2024 was €1.36 Mil.

Edesa Biotech Change In Receivables Historical Data

The historical data trend for Edesa Biotech's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Edesa Biotech Change In Receivables Chart

Edesa Biotech Annual Data

Trend

Aug14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Change In Receivables

Get a 7-Day Free Trial

0.01

0.11

-2.75

2.05

0.53

Edesa Biotech Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															0.07	0.01	-0.55	-0.09	-0.35

Edesa Biotech Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.99 Mil.

Edesa Biotech (STU:RBTQ) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Edesa Biotech's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	1.023	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Edesa Biotech's accounts receivable are only considered to be worth 75% of book value:

Edesa Biotech's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	2.576	-	1.979	+	0.75 * 1.023	+	0.5 * 0
=	1.36

Edesa Biotech Change In Receivables Related Terms

Thank you for viewing the detailed overview of Edesa Biotech's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Edesa Biotech (STU:RBTQ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Edesa Biotech Inc (STU:RBTQ) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

EDSA:USA

Address

100 Spy Court, Markham, ON, CAN, L3R 5H6

Website

https://www.edesabiotech.com

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB01, is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis. The company operates in a single segment: research and development, manufacturing, and commercialization of innovative pharmaceutical products. The company's EB05 candidate is a monoclonal antibody therapy for hospitalized COVID-19 patients.

Edesa Biotech (STU:RBTQ) Headlines

No Headlines